PRMT5 and B-cell chronic lymphocytic leukemia: In summary, the downstream molecular effects in cells that have genomically activated levels of PRMT5 resembled at least partly the expression pattern in CLL donors with high PRMT5 expression and inversely reflected what we observed upon PRMT5 inhibition.